123 related articles for article (PubMed ID: 29966685)
1. Regulatory challenges of nanomedicines and their follow-on versions: A generic or similar approach?
Mühlebach S
Adv Drug Deliv Rev; 2018 Jun; 131():122-131. PubMed ID: 29966685
[TBL] [Abstract][Full Text] [Related]
2. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives.
Souto EB; Blanco-Llamero C; Krambeck K; Kiran NS; Yashaswini C; Postwala H; Severino P; Priefer R; Prajapati BG; Maheshwari R
Acta Biomater; 2024 May; 180():1-17. PubMed ID: 38604468
[TBL] [Abstract][Full Text] [Related]
3. Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision.
Gaspar RS; Silva-Lima B; Magro F; Alcobia A; da Costa FL; Feio J
Front Med (Lausanne); 2020; 7():590527. PubMed ID: 33330550
[TBL] [Abstract][Full Text] [Related]
4. Strategic aspects for the commercialization of nanomedicines.
Hemmrich E; McNeil S
J Control Release; 2024 May; 369():617-621. PubMed ID: 38588826
[TBL] [Abstract][Full Text] [Related]
5. Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.
Bartlett JA; Brewster M; Brown P; Cabral-Lilly D; Cruz CN; David R; Eickhoff WM; Haubenreisser S; Jacobs A; Malinoski F; Morefield E; Nalubola R; Prud'homme RK; Sadrieh N; Sayes CM; Shahbazian H; Subbarao N; Tamarkin L; Tyner K; Uppoor R; Whittaker-Caulk M; Zamboni W
AAPS J; 2015 Jan; 17(1):44-64. PubMed ID: 25421459
[TBL] [Abstract][Full Text] [Related]
6. Understanding the Uptake of Nanomedicines at Different Stages of Brain Cancer Using a Modular Nanocarrier Platform and Precision Bispecific Antibodies.
Houston ZH; Bunt J; Chen KS; Puttick S; Howard CB; Fletcher NL; Fuchs AV; Cui J; Ju Y; Cowin G; Song X; Boyd AW; Mahler SM; Richards LJ; Caruso F; Thurecht KJ
ACS Cent Sci; 2020 May; 6(5):727-738. PubMed ID: 32490189
[TBL] [Abstract][Full Text] [Related]
7. Nanopharmaceuticals (part 2): products in the pipeline.
Weissig V; Guzman-Villanueva D
Int J Nanomedicine; 2015; 10():1245-57. PubMed ID: 25709446
[TBL] [Abstract][Full Text] [Related]
8. Achieving Precision Healthcare through Nanomedicine and Enhanced Model Systems.
Svensson E; von Mentzer U; Stubelius A
ACS Mater Au; 2024 Mar; 4(2):162-173. PubMed ID: 38496040
[TBL] [Abstract][Full Text] [Related]
9. Nanomedicines: The magic bullets reaching their target?
Flühmann B; Ntai I; Borchard G; Simoens S; Mühlebach S
Eur J Pharm Sci; 2019 Feb; 128():73-80. PubMed ID: 30465818
[TBL] [Abstract][Full Text] [Related]
10. Single Particle Chemical Characterisation of Nanoformulations for Cargo Delivery.
Saunders C; de Villiers CA; Stevens MM
AAPS J; 2023 Oct; 25(6):94. PubMed ID: 37783923
[TBL] [Abstract][Full Text] [Related]
11. Differences in Physico-Chemical Properties and Immunological Response in Nanosimilar Complex Drugs: The Case of Liposomal Doxorubicin.
Lipsa D; Magrì D; Della Camera G; La Spina R; Cella C; Garmendia-Aguirre I; Mehn D; Ruiz-Moreno A; Fumagalli F; Calzolai L; Gioria S
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686418
[TBL] [Abstract][Full Text] [Related]
12. Classification system for nanotechnology-enabled health products with both scientific and regulatory application.
Rodríguez-Gómez FD; Penon O; Monferrer D; Rivera-Gil P
Front Med (Lausanne); 2023; 10():1212949. PubMed ID: 37601794
[TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicles: powerful candidates in nano-drug delivery systems.
Liu X; Cao Y; Wang S; Liu J; Hao H
Drug Deliv Transl Res; 2024 Feb; 14(2):295-311. PubMed ID: 37581742
[TBL] [Abstract][Full Text] [Related]
14. Revealing Population Heterogeneity in Vesicle-Based Nanomedicines Using Automated, Single Particle Raman Analysis.
Saunders C; Foote JEJ; Wojciechowski JP; Cammack A; Pedersen SV; Doutch JJ; Barriga HMG; Holme MN; Penders J; Chami M; Najer A; Stevens MM
ACS Nano; 2023 Jun; 17(12):11713-11728. PubMed ID: 37279338
[TBL] [Abstract][Full Text] [Related]
15. Regulatory considerations for generic products of non-biological complex drugs.
Liu YH; Chen YS; Tseng T; Jiang ML; Gau CS; Chang LC
J Food Drug Anal; 2023 Mar; 31(1):20-31. PubMed ID: 37224550
[TBL] [Abstract][Full Text] [Related]
16. Precision Nanotoxicology in Drug Development: Current Trends and Challenges in Safety and Toxicity Implications of Customized Multifunctional Nanocarriers for Drug-Delivery Applications.
Ahmad A; Imran M; Sharma N
Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36432653
[TBL] [Abstract][Full Text] [Related]
17. Intravenous Iron-Carbohydrate Nanoparticles and Their Similars. What Do We Choose?
Mehedinti AM; Capusa C; Andreiana I; Mircescu G
Maedica (Bucur); 2022 Jun; 17(2):436-448. PubMed ID: 36032600
[TBL] [Abstract][Full Text] [Related]
18. Polymeric Nanoparticles in Cancer Chemotherapy: A Narrative Review.
Yousefi Rizi HA; Hoon Shin D; Yousefi Rizi S
Iran J Public Health; 2022 Feb; 51(2):226-239. PubMed ID: 35866132
[TBL] [Abstract][Full Text] [Related]
19. Weak Polyelectrolytes as Nanoarchitectonic Design Tools for Functional Materials: A Review of Recent Achievements.
Sanchez-Ballester NM; Sciortino F; Mir SH; Rydzek G
Molecules; 2022 May; 27(10):. PubMed ID: 35630741
[TBL] [Abstract][Full Text] [Related]
20. Need for Expansion of Pharmacy Education Globally for the Growing Field of Nanomedicine.
Barton AE; Borchard G; Wacker MG; Pastorin G; Saleem IY; Chaudary S; Elbayoumi T; Zhao Z; Flühmann B
Pharmacy (Basel); 2022 Jan; 10(1):. PubMed ID: 35202067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
